Pre- versus post-dilution haemofiltration: a prospective randomised cross-over study

ISRCTN ISRCTN38768865
DOI https://doi.org/10.1186/ISRCTN38768865
Secondary identifying numbers N/A
Submission date
05/07/2005
Registration date
06/07/2005
Last edited
14/09/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mrs Anne-Cornelie de Pont
Scientific

Academic Medical Center
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Phone +31 (0)20 5669111 tracer 59229
Email a.c.depont@amc.uva.nl

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymPREPOST
Study objectivesPredilution prolongs extracorporeal circuit survival time during continuous venovenous hemofiltration, due to a decrease in platelet activation and thrombin generation.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedAcute renal failure
InterventionContinuous venovenous haemofiltration, predilution versus postdilution
Intervention typeOther
Primary outcome measureExtracorporeal circuit survival time
Secondary outcome measuresPlatelet activation, thrombin generation, urea clearance
Overall study start date01/12/2000
Completion date01/01/2002

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants7
Key inclusion criteriaEight critically ill patients with an indication for renal replacement therapy
Key exclusion criteriaRecent bleeding, treatment with aspirin within one week before inclusion or with therapeutic doses of unfractionated or low molecular weight heparin within 12 hours before inclusion or results of routine coagulation tests such as protrombin time (PT) and activated partial thromboplastin time (APTT) exceeding twice the upper limit of normal
Date of first enrolment01/12/2000
Date of final enrolment01/01/2002

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Academic Medical Center
Amsterdam
1105 AZ
Netherlands

Sponsor information

Academic Medical Centre (Netherlands)
Hospital/treatment centre

Prof. dr. M.B. Vroom
Academic Medical Centre
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Phone +31 (0)20 5669111 tracer 59155
Email m.b.vroom@amc.uva.nl
Website http://www.amc.uva.nl
ROR logo "ROR" https://ror.org/03t4gr691

Funders

Funder type

Hospital/treatment centre

Internally funded (Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan